BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma today announced its commitment to achieving a net-zero climate target by 2050. It involves developing an extensive decarbonization plan across the ...

Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...

LEO Pharma has announces that it will acquire Replay, a gene therapy company focused on developing transformative treatments ...

LEO Pharma has acquired Replay, a herpes simplex virus (HSV) gene therapy platform, for $50m upfront, expanding the company’s ...

April 30 (Reuters) - Danish drugmaker LEO Pharma said on Thursday it had agreed to buy U.S. drug developer Replay for $50 million upfront, adding an experimental treatment platform for rare genetic ...

Leo Pharma is actively seeking more acquisition targets, with as much as 5 billion kroner ($800 million) to spend on ...

Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO ...

In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while ...

The campaign focuses on educating the one in 10 U.S. adults living with chronic hand eczema (CHE), particularly the one in three patients who have never heard the specific name of their condition.

Back in February, Leo Pharma revealed that its JAK-inhibitor cream delgocitinib met its primary and secondary endpoints in a phase 3 trial in chronic hand eczema, putting pressure on Incyte’s approved ...

Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific type of eczema. Called “Talk to the Hand,” this campaign aims to spread ...

LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments ...